Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Mianus Capital is a specialist life-sciences investment firm founded in 2012 and headquartered in Wisconsin, USA. The firm focuses on Seed and Pre-A investment opportunities in early-stage biotechnology innovation globally. Mianus Capital partners with MERIT CRO, Inc., a leader in drug development and clinical research, to enhance its investment strategies and support its portfolio companies.
The firm operates both a venture capital and a private equity arm, with its most notable vehicle being the Mianus Clarity Fund, which specifically targets the ophthalmology market. This fund was publicly launched at the ARVO 2023 Annual Meeting, showcasing Mianus Capital's commitment to advancing innovation in this therapeutic area. Mianus Capital aims to integrate Western biotech innovation with China's clinical ecosystem, thereby accelerating the development of transformative therapies.
Mianus Capital invests primarily in early-stage biotech companies, specifically targeting Seed and Pre-A funding rounds. The firm emphasizes a diversified portfolio across various therapeutic areas, particularly in ophthalmology. Leveraging insights from its strategic partner, MERIT CRO, Mianus Capital supports clinical development and operational needs of its portfolio companies. This partnership allows Mianus to provide unique access to clinical trial expertise and operational support, enhancing the ability of its investments to navigate the complex drug development process.
The firm aims to combine Western biotech innovation with China's clinical ecosystem, which positions it uniquely in the market. Mianus Capital's investment strategy is characterized by a focus on early-stage biotechnology innovation, with a strong emphasis on leveraging its partnership with MERIT CRO to enhance clinical development and accelerate the delivery of transformative therapies.
Steve Yang - Co-founder and CEO. Steve has extensive experience in the life sciences sector, having previously worked with leading biotech firms. He has a strong background in venture capital and operational management.
Yijun Huang - Co-founder. Yijun brings a wealth of knowledge in biotechnology and has been instrumental in shaping Mianus Capital's investment strategy.
David Bingaman - VP, Commercial Development. David has a background in commercial strategy and business development within the biotech industry, focusing on market access and commercialization strategies.
Leon Tang - VP, Business Development. Leon specializes in identifying and evaluating new investment opportunities, leveraging his extensive network in the biotech sector.
Grace Gui - VP, Capital Advisory. Grace provides strategic guidance on capital raising and financial structuring for portfolio companies, drawing on her experience in investment banking.
To pitch Mianus Capital, founders should send an email to info@mianuscapital.com. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and alignment with Mianus Capital's investment focus. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
In October 2023, Mianus Capital and MERIT CRO announced the formation of an Ophthalmology Scientific Advisory Council (SAC), which includes top innovators and experts in the field. This initiative aims to enhance the firm's capabilities in ophthalmology investments and clinical development.
The Mianus Clarity Fund was publicly launched at the ARVO 2023 Annual Meeting, focusing on innovation in the global ophthalmology market. This fund represents Mianus Capital's commitment to advancing therapeutic solutions in this critical area.
What are Mianus Capital's investment criteria?
Mianus Capital focuses on early-stage biotech companies, specifically in the Seed and Pre-A funding stages. The firm seeks to invest in companies that demonstrate innovative approaches in biotechnology, particularly those that can leverage the expertise of its partner, MERIT CRO, in drug development and clinical research.
How can founders apply or pitch to Mianus Capital?
Founders can reach out to Mianus Capital via email at info@mianuscapital.com to initiate discussions about potential investment opportunities. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and how the company aligns with Mianus Capital's focus areas.
What makes Mianus Capital different from other venture firms?
Mianus Capital differentiates itself through its strategic partnership with MERIT CRO, which provides deep expertise in drug development and clinical trials. This partnership allows Mianus to offer operational support and insights that are critical for early-stage biotech companies navigating the complexities of clinical development.
What is Mianus Capital's geographic scope?
The firm invests globally, with a particular focus on opportunities in the United States and China. This geographic reach allows Mianus Capital to tap into diverse markets and leverage the strengths of both Western and Chinese biotech ecosystems.
What is the fund size and check size for investments?
While specific fund sizes are not publicly disclosed, Mianus Capital targets Seed and Pre-A funding rounds, which typically involve investments ranging from hundreds of thousands to several million dollars, depending on the stage and needs of the portfolio company.
What kind of post-investment involvement does Mianus Capital have?
Mianus Capital is actively involved with its portfolio companies, providing access to clinical trial expertise and operational support through its partnership with MERIT CRO. This involvement helps companies navigate the drug development process more effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.